GLP-3 RT (15mg)
Especificaciones técnicas
| Pureza (HPLC) | ≥97% (HPLC) |
| Número CAS | 2381089-83-2 |
| Forma | White lyophilized powder |
| Almacenamiento | -20°C |
| Secuencia | Modified triple incretin agonist |
| Peso molecular | 4,803.56 g/mol |
| Forma salina | Acetate |
| Solubilidad | Soluble in aqueous buffer |
GLP-3 RT (15mg)
Precio de lista en EUR · HU, SK, CZ, PL
- Eurozone (EUR)378,00 EUR
- Hungría (HU)378,00 EUR≈ 151 200 Ft
- Eslovaquia (SK)378,00 EUR
- Chequia (CZ)378,00 EUR≈ 9 450 Kč
- Polonia (PL)378,00 EUR≈ 1606,50 zł
Mismo precio de lista en EUR para envío a Hungría, Eslovaquia, República Checa y Polonia. El pago se cobra en EUR.
HUF/CZK/PLN indicativos convertidos desde EUR; Eslovaquia usa EUR. Tasas aproximadas. Cobro en EUR.
Triple GLP-1 / GIP / Glucagon receptor agonist for advanced metabolic research. 15mg vial, ≥99% HPLC purity.
Estrictamente para investigación de laboratorio.
No apto para consumo humano, uso veterinario ni diagnóstico.
From the Peptide Explorer
The first triple-incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data demonstrated the largest weight reductions reported for any anti-obesity molecule, positioning it as a next-generation metabolic research compound.
Key Mechanisms
- ›GIP receptor agonism
- ›GLP-1 receptor agonism
- ›Glucagon receptor agonism (energy expenditure)
- ›Hepatic lipid metabolism enhancement
- ›Appetite suppression via CNS pathways
Primary Research Areas
- ›Obesity
- ›NASH
- ›Metabolic syndrome
- ›Triple-incretin signaling
- ›Energy expenditure
Key Research Findings
- Phase 2: up to 24.2% body weight reduction at 48 weeks (highest reported for any molecule)
- Glucagon component uniquely increases energy expenditure
- Significant reduction in liver fat content in NAFLD models
Research Overview
The first triple-incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data demonstrated the largest weight reductions reported for any anti-obesity molecule, positioning it as a next-generation metabolic research compound.
Origin: Triple GIP/GLP-1/glucagon receptor agonist by Eli Lilly
Mechanism of Action
- GIP receptor agonism
- GLP-1 receptor agonism
- Glucagon receptor agonism (energy expenditure)
- Hepatic lipid metabolism enhancement
- Appetite suppression via CNS pathways
Primary Research Areas
- Obesity
- NASH
- Metabolic syndrome
- Triple-incretin signaling
- Energy expenditure
Key Published Findings
- Phase 2: up to 24.2% body weight reduction at 48 weeks (highest reported for any molecule)
- Glucagon component uniquely increases energy expenditure
- Significant reduction in liver fat content in NAFLD models
Research Protocol
Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
2-8°C
Important Notice
Retatrutide (15mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Especificaciones de investigación
Synthesized for strict analytical consistency. Verified via HPLC/MS.Ver estándares de calidad →
Manipulación y almacenamiento
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Soluble in aqueous buffer